Posts Feed
Comments Feed

Archive for the 'Lung Cancer' Category

CIHR Report Underscores Need For Action Plan On Lung Health And Access To Smoking Cessation Programs And Affordable Medications, Canada

Nov 25th 2008Drug InformationLung Cancer

The Lung Association today commended the Canadian Institute for Health Information (CIHI) on its newly released report examining health disparity and its relation to low socio-economic status. The report underscores the need for a national action plan on lung health, and the need for increased access to affordable smoking cessation medications and programs. The CIHR Report found that there is a key link between low socio-economic status and lung diseases such as asthma and COPD.

More: continued here

No Comments »

Survey Shows Lung Cancer Patients Blamed For Their Diagnosis

Nov 21st 2008Drug InformationLung Cancer

Survey results released today show that the general population blames lung cancer patients for their diagnosis, confirming the stigma that patients reportedly feel. Findings also demonstrate a lack of public support for patients and a need for greater research for the number one cancer killer.

More: continued here

No Comments »

Overall Survival In 1st-line NSCLC Reaches 15 Months With Erbitux, Merck Serrono Informs

Nov 21st 2008Drug InformationLung Cancer

Data presented today at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology show that patients with non-small cell lung cancer (NSCLC) who were given Erbitux® (cetuximab) in addition to a standard 1st-line platinum-based chemotherapy lived significantly longer than those who received chemotherapy alone.1 This effect was more pronounced in patients treated with Erbitux who developed early acne-like rash, resulting in median overall survival of 15 months.

More: continued here

No Comments »

« Prev - Next »

1